JP7737143B2 - がん治療のための組成物および方法 - Google Patents

がん治療のための組成物および方法

Info

Publication number
JP7737143B2
JP7737143B2 JP2021536007A JP2021536007A JP7737143B2 JP 7737143 B2 JP7737143 B2 JP 7737143B2 JP 2021536007 A JP2021536007 A JP 2021536007A JP 2021536007 A JP2021536007 A JP 2021536007A JP 7737143 B2 JP7737143 B2 JP 7737143B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
ribo
checkpoint inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515188A5 (https=
JP2022515188A (ja
Inventor
アール ストレイヤー，デイビッド
ケイ イークアルズ，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIM Immunotech Inc
Original Assignee
AIM Immunotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AIM Immunotech Inc filed Critical AIM Immunotech Inc
Publication of JP2022515188A publication Critical patent/JP2022515188A/ja
Publication of JP2022515188A5 publication Critical patent/JP2022515188A5/ja
Application granted granted Critical
Publication of JP7737143B2 publication Critical patent/JP7737143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021536007A 2018-12-21 2019-12-20 がん治療のための組成物および方法 Active JP7737143B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862783834P 2018-12-21 2018-12-21
US62/783,834 2018-12-21
US201962792760P 2019-01-15 2019-01-15
US201962792765P 2019-01-15 2019-01-15
US62/792,760 2019-01-15
US62/792,765 2019-01-15
US201962869909P 2019-07-02 2019-07-02
US62/869,909 2019-07-02
US201962885143P 2019-08-09 2019-08-09
US62/885,143 2019-08-09
PCT/US2019/068044 WO2020132560A2 (en) 2018-12-21 2019-12-20 Compositions and methods for cancer therapy

Publications (3)

Publication Number Publication Date
JP2022515188A JP2022515188A (ja) 2022-02-17
JP2022515188A5 JP2022515188A5 (https=) 2022-12-27
JP7737143B2 true JP7737143B2 (ja) 2025-09-10

Family

ID=69326681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536007A Active JP7737143B2 (ja) 2018-12-21 2019-12-20 がん治療のための組成物および方法

Country Status (12)

Country Link
US (1) US20220096518A1 (https=)
EP (1) EP3897854A2 (https=)
JP (1) JP7737143B2 (https=)
KR (1) KR20210106531A (https=)
CN (1) CN113474048A (https=)
AU (1) AU2019403445A1 (https=)
BR (1) BR112021012103A2 (https=)
CA (1) CA3124408A1 (https=)
MX (1) MX2021007565A (https=)
NL (1) NL2024544B1 (https=)
SG (1) SG11202106295WA (https=)
WO (1) WO2020132560A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813279B2 (en) 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
WO2022061309A1 (en) * 2020-09-21 2022-03-24 Aim Immunotech Inc. Compositions and methods for treating cancer
CN118962103B (zh) * 2022-03-15 2025-07-22 上海君赛生物科技有限公司 肿瘤特异性免疫细胞标志物及其用途
CN115645515A (zh) * 2022-12-28 2023-01-31 北京圣美细胞生命科学工程研究院有限公司 肿瘤治疗组合物及应用、药物组合物和细胞生长抑制方法
EP4720300A1 (en) * 2023-06-05 2026-04-08 GMP Biotechnology Limited Anti-cancer tgfb2 agents with immunotherapeutics
CN118976108B (zh) * 2024-08-02 2025-04-01 哈尔滨工业大学 一种用于激活抗肿瘤氧化应激和长期免疫反应的聚合前药纳米反应器的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5258369A (en) * 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8759379B2 (en) * 2008-01-04 2014-06-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
AU2009308105B2 (en) * 2008-10-23 2016-07-07 Aim Immunotech Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20140170191A1 (en) * 2008-10-23 2014-06-19 Hemispher Biopharma, Inc. Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
BG111827A (bg) 2014-09-24 2016-03-31 Динко Бахов Метод и устройство за изпридане на прежда от щапелни влакна
GB201503776D0 (en) * 2015-03-05 2015-04-22 Pci Biotech As Compound and method
US20180044350A1 (en) 2015-03-10 2018-02-15 Pottayil Govindan Nair Sasikumar Therapeutic cyclic compounds as immunomodulators
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
BR112017019307A2 (pt) 2015-03-10 2018-05-02 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
EA201791629A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016187656A1 (en) * 2015-05-22 2016-12-01 La Trobe University Method of diagnosis of breast cancer
KR102129195B1 (ko) * 2016-02-15 2020-07-01 에프케이디 테라피즈 리미티드, 향상된 인터페론 치료
WO2018039205A1 (en) * 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
MY192158A (en) * 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASEY AGER; ET AL，31ST ANNUAL MEETING AND ASSOCIATED PROGRAMS OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC 2016): PART TWO，JOURNAL FOR IMMUNOTHERAPY OF CANCER，英国，BIOMED CENTRAL LTD，2016年11月16日，VOL:4, NR:1，PAGE(S):73(107-221)，https://jitc.bmj.com/content/jitc/4/Suppl_1/73.full.pdf
YARA ABDOU; ET AL，CHEMOKINE MODULATION TO ENHANCE THE EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER，CANCER IMMUNOLOGY RESEARCH，AMERICAN ASSOCIATION FOR CANCER RESEARCH，2018年09月30日，VOL:7, NR:2，PAGE(S):1-4，https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B203

Also Published As

Publication number Publication date
AU2019403445A2 (en) 2021-08-05
WO2020132560A3 (en) 2020-07-30
NL2024544A (en) 2020-07-10
SG11202106295WA (en) 2021-07-29
BR112021012103A2 (pt) 2021-09-08
NL2024544B1 (en) 2021-03-15
MX2021007565A (es) 2021-10-13
JP2022515188A (ja) 2022-02-17
KR20210106531A (ko) 2021-08-30
EP3897854A2 (en) 2021-10-27
CA3124408A1 (en) 2020-06-25
CN113474048A (zh) 2021-10-01
AU2019403445A1 (en) 2021-07-29
US20220096518A1 (en) 2022-03-31
WO2020132560A2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
JP7737143B2 (ja) がん治療のための組成物および方法
JP6687612B2 (ja) 組合せ
CN106659772B (zh) 在疾病和紊乱的治疗中调节肾酶的组合物和方法
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
CN109071666A (zh) 人脊髓灰质炎病毒受体（pvr）特异性抗体
US20250179173A1 (en) Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
KR20200084880A (ko) 종양을 치료하는 방법
CN114450028A (zh) Lag-3拮抗剂治疗的定量空间剖析
WO2020211804A1 (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN115052628B (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN112996504A (zh) 通过抑制泛素缀合酶e2 k(ube2k)治疗癌症的方法
CN115956088A (zh) 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
KR20250052418A (ko) 항-ccr8 항체 및 그의 용도
US20210196744A1 (en) Compositions for cancer therapy and methods
US20210340232A1 (en) Monoclonal antibodies against human dickkopf3 and uses thereof
CN110603447A (zh) 用抗肾酶抗体和抗pd1抗体治疗癌症的组合物和方法
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
HK40050404A (en) Compositions and methods for cancer therapy
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
WO2024218697A1 (en) Methods and systems for improving anti-cancer therapies
WO2023168404A1 (en) Methods of treating a tumor
HK40054961A (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250822

R150 Certificate of patent or registration of utility model

Ref document number: 7737143

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150